Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion

Am J Hematol. 2009 May;84(5):295-7. doi: 10.1002/ajh.21373.

Abstract

The t(7;11)(p15;p15) translocation has been reported as a rare and recurrent chromosomal abnormality in acute myeloid leukemia (AML) patients. The NUP98-HOXA9 fusion gene with t(7;11)(p15;p15) was identified and revealed to be essential for leukemogenesis and myeloproliferative disease. To date, t(7;11)(p15;p15) with NUP98-HOXA11 fusion has been reported only in one case of ph-negative chronic myeloid leukemia (CML). Here, we report a case of a 3-year-old girl with juvenile myelomonocytic leukemia (JMML) carrying t(7;11)(p15;p15) abnormality with NUP98-HOXA11 fusion. AML chemotherapy followed by bone marrow transplantation (BMT) was found to be effective in treating this disorder, and she remains in complete remission for 3 years after BMT. We suggest the possibility that AML chemotherapy might be effective for treating JMML with t(7;11)(p15;p15) abnormality and NUP98-HOXA11 fusion.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Transplantation
  • Child, Preschool
  • Chromosomes, Human, Pair 11*
  • Chromosomes, Human, Pair 7*
  • Combined Modality Therapy
  • Female
  • Homeodomain Proteins / genetics*
  • Humans
  • Leukemia, Myelomonocytic, Juvenile / genetics*
  • Leukemia, Myelomonocytic, Juvenile / physiopathology
  • Leukemia, Myelomonocytic, Juvenile / therapy*
  • Nuclear Pore Complex Proteins / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Remission Induction
  • Translocation, Genetic*

Substances

  • Antineoplastic Agents
  • Homeodomain Proteins
  • NUP98-HOXA11 fusion protein, human
  • Nuclear Pore Complex Proteins
  • Oncogene Proteins, Fusion